Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PtIV-MSA-2 conjugate I
- Development stage
- Preclinical
- Modality
- Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Administration
- Intravenous (preclinical Data), Potential Future: Oral, Peritumoral (not Validated In Human Use)[1][3][6]
01
Overview
PtIV-MSA-2 conjugate I is a synthetic bifunctional small molecule designed as a single-molecule **platinum(IV) prodrug** combining the DNA-damaging effects of **cisplatin (CDDP)** with the innate immune-activating properties of a **STING agonist** (MSA-2)[1][2][6]. Upon intracellular reduction in the tumor microenvironment, the prodrug releases platinum(II) (cisplatin) for DNA crosslinking and damage, and free MSA-2, which stimulates the STING (Stimulator of Interferon Genes) pathway, amplifying antitumor immunity through type I interferon signaling. This dual mechanism results in enhanced immunogenic cell death and innate/adaptive immune activation, leading to potent cytotoxic and antitumoral effects in preclinical models, particularly pancreatic cancer. Developed for an improved chemotherapeutic and immunotherapeutic profile beyond platinum or STING agents alone, this molecule aims to maximize efficacy and minimize systemic immunotoxicity by targeted, intracellular, reduction-dependent activation[1][2].
- Other names
- PtIV-MSA-2 conjugate IPtIV-MSA2 conjugate IPtIV-MSA 2 conjugate IPt-MSA-2 conjugate IPt-MSA2 conjugate IPt-MSA 2 conjugate Iplatinum(IV)-MSA-2 conjugate I
02
Targets
STING (Stimulator of interferon genes protein)
Beyond the preview
Go deeper on PtIV-MSA-2 conjugate I.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PtIV-MSA-2 conjugate I.